IP Library Granted Patent US 9,233,088
Granted Patent B2
US 9,233,088 · App. 14/101,234 · Granted Jan 12, 2016

Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis

Inventors: Tadeusz Studzinski (Lublin, PL); Jose Luis Valverde Piedra (Lublin, PL); Stefan Pierzynowski (Lund, SE)
Assignee: PROTISTA BIOTECHNOLOGY AB
A61K31/194A23L1/3051A61K31/198A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,233,088
App. No.
14/101,234
Granted
Jan 12, 2016
Kind
B2
Abstract

A method for obtaining improved bone quality in a vertebrate, including mammal and bird, the method comprising administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof. Also contemplated is a method for modulating bone quality in a vertebrate, including mammal and bird, comprising administering to the vertebrate, including mammal and bird, in the need thereof, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, for modulating the bone quality as well as a compositions for use in treatment.

Claims (26)

1. A method of reducing the risk of or treating osteoporosis, the method comprising:

administering a composition comprising alpha-ketoglutaric acid (AKG) or a pharmaceutically acceptable salt thereof, to a vertebrate in need thereof, wherein the composition is administered at 0.01-0.2 g/kg bodyweight per daily dose.

2. The method according to claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier and/or additives.

3. The method according to claim 1 , wherein the composition is a food or a feed supplement.

4. The method according to claim 1 wherein the composition is a dietary supplement and/or a component in the form of solid food and/or beverage.

5. A method of improving bone quality in a vertebrate, comprising:

administering a composition comprising alpha-ketoglutaric acid (AKG) or a pharmaceutically acceptable salt thereof, to a vertebrate in the need thereof, wherein the composition is administered at 0.01-0.2 g/kg bodyweight per daily dose.

6. The method according to claim 5 , wherein the composition further comprises pharmaceutically acceptable carrier and/or additives.

7. The method according to claim 5 , wherein the composition is a food or a feed supplement.

8. The method according to claim 5 , wherein the composition is a dietary supplement and/or a component in form of solid food and/or beverage.

9. The method according to claim 1 , wherein the pharmaceutically acceptable salt thereof is a mono- or di-metal salt of alpha-ketoglutaric acid (AKG).

10. The method according to claim 1 , wherein the pharmaceutically acceptable salt thereof is an amino-acid salt of alpha-ketoglutaric acid (AKG).

11. The method according to claim 5 , wherein the pharmaceutically acceptable salt thereof is a mono- or di-metal salt of alpha-ketoglutaric acid (AKG).

12. The method according to claim 5 , wherein a pharmaceutically acceptable salt thereof is an amino-acid salt of alpha-ketoglutaric acid (AKG).

13. The method according to claim 1 , wherein the vertebrate is affected with osteoporosis.

14. The method according to claim 5 , wherein the vertebrate is affected with osteoporosis.

15. A method of treating osteopenia and preventing osteoporosis, the method comprising:

administering a composition comprising alpha-ketoglutaric acid (AKG) or a pharmaceutically acceptable salt thereof, to a vertebrate in need thereof, wherein the composition is administered at 0.01-0.26 g/kg bodyweight per a daily dose.

16. The method according to claim 15 , wherein the composition further comprises a pharmaceutically acceptable carrier and/or additives.

17. The method according to claim 15 , wherein the composition is a food or a feed supplement.

18. The method according to claim 15 , wherein the composition is a dietary supplement and/or a component in the form of solid food and/or beverage.

19. The method according to claim 15 , wherein the pharmaceutically acceptable salt thereof is a mono- or di-metal salt of alpha-ketoglutaric acid (AKG).

20. The method according to claim 15 , wherein the pharmaceutically acceptable salt thereof is an amino-acid salt of alpha-ketoglutaric acid (AKG).

21. The method according to claim 5 , wherein the vertebrate is a mammal or a bird.

22. The method according to claim 1 , 5 , or 15 , wherein the a composition comprising AKG or a pharmaceutically acceptable salt thereof further comprises glutamine.

23. The method according to claim 1 , 5 , or 15 , wherein the a composition comprising AKG or a pharmaceutically acceptable salt thereof further comprises ornithine.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2016
From: PROTISTA BIOTECHNOLOGY AB
To: PROTISTA CORPORATION AB
Reel/Frame 039750/0814 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2015
From: STUDZINSKI, TADEUSZ; PIEDRA, JOSE LUIS VALVERDE; PIERZYNOWSKI, STEFAN
To: AB GRUNDSTENEN 91165
Reel/Frame 035590/0597 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2015
From: PROTISTA BIOTECHNOLOGY AB
To: ESSENTYS AB
Reel/Frame 035590/0690 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2015
From: ATTERYD, LENNART
To: PROTISTA BIOTECHNOLOGY AB
Reel/Frame 035590/0811 →
CHANGE OF NAME Recorded May 7, 2015
From: AB GRUNDSTENEN 91165
To: PROTISTA BIOTECHNOLOGY AB
Reel/Frame 035614/0307 →
COURT APPOINTMENT Recorded May 7, 2015
From: ESSENTYS AB
To: ATTERYD, LENNART
Reel/Frame 035615/0668 →
Priority Claims (3)
SE 0103932-0 · Nov 23, 2001 · national
SE 0104385-0 · Dec 21, 2001 · national
SE 0201713-5 · Jun 6, 2002 · national
Continuity (2)
Continuation 10496350
Related Publication 20140194521A1 · Jul 10, 2014